Pharma Mar SA (PHM) AI Stock Analysis

• Market Cap: $1.58B
• Dividend Yield: 0.92%
• Average Volume (3M): 52.96K
• Price to Earnings (P/E): 37.1
• Beta (1Y): 1.11
• Revenue Growth: 19.18%
• EPS Growth: N/A
• Country: ES
• Employees: 500
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 1.32
• Shares Outstanding: 18,222,227
• 10 Day Avg. Volume: 59,850
• 30 Day Avg. Volume: 52,961
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.84
• Enterprise Value/Revenue: 6.98
• Enterprise Value/Gross Profit: 7.35
• Enterprise Value/Ebitda: 27.95
• 1Y Price Target: $89.19
• Price Target Upside: 2.76% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 64 Neutral
• Price Target: €89.00 ▲(2.53% Upside)

Pharma Mar SA's stock score is primarily driven by its strong financial performance, particularly in profitability and balance sheet stability. However, challenges in cash flow management and a high P/E ratio weigh on the overall score. Technical indicators suggest moderate bullish momentum, but valuation concerns limit potential upside.

Pharma Mar SA Business Overview & Revenue Model

Company Description

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.

How the Company Makes Money

Pharma Mar SA generates revenue through the development, production, and commercialization of its pharmaceutical products. The company primarily earns money by licensing its proprietary drugs to pharmaceutical partners and through direct sales of its products in markets where it retains commercialization rights. Additionally, Pharma Mar benefits from royalties on sales made by its partners, as well as milestone payments tied to the development and commercialization progress achieved by its collaborators. The company's revenue is further supported by strategic partnerships and collaborations which help expand its research capabilities and market reach.

Pharma Mar SA Financial Statement Overview

Summary

Pharma Mar SA demonstrates strong profitability with robust gross and net profit margins. The balance sheet is stable with manageable debt levels and strong equity returns. However, cash flow management presents challenges, with declining free cash flow and operating cash flow ratios. The company should focus on enhancing operational efficiencies and cash flow generation to sustain growth.

Income Statement

Pharma Mar SA shows strong gross profit margins consistently above 93%, indicating efficient cost management. The TTM net profit margin improved to 22.20%, reflecting enhanced profitability. Revenue growth is positive at 7.69% TTM, recovering from previous declines. However, EBIT and EBITDA margins, though improving, remain lower than historical highs, suggesting room for operational efficiency improvements.

Balance Sheet

The company maintains a stable debt-to-equity ratio around 0.25, indicating prudent leverage management. Return on equity has improved to 21.28% TTM, showcasing effective use of equity capital. The equity ratio remains healthy, suggesting a strong capital structure. However, the decline in total assets over recent years could be a concern for future growth.

Cash Flow

Operating cash flow is positive but has decreased significantly, impacting the operating cash flow to net income ratio. Free cash flow growth is negative, indicating potential liquidity challenges. The free cash flow to net income ratio is low, suggesting limited cash generation relative to net income. This highlights the need for improved cash management strategies.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	189.27M	174.85M	158.15M	196.34M	229.83M	269.96M
Gross Profit	179.76M	166.67M	148.54M	182.70M	213.39M	256.24M
EBITDA	47.25M	21.23M	4.55M	52.07M	104.08M	155.94M
Net Income	42.01M	26.13M	1.14M	49.36M	92.86M	137.26M
Balance Sheet
Total Assets	348.25M	349.64M	340.52M	393.26M	368.39M	330.26M
Cash, Cash Equivalents and Short-Term Investments	128.08M	154.53M	162.56M	182.42M	201.88M	195.52M
Total Debt	51.40M	51.08M	43.67M	42.63M	49.33M	56.66M
Total Liabilities	146.72M	141.28M	147.08M	170.30M	190.47M	227.54M
Stockholders Equity	201.53M	208.36M	193.44M	222.96M	177.92M	102.72M
Cash Flow
Free Cash Flow	1.28M	-9.48M	-29.40M	29.47M	17.87M	275.94M
Operating Cash Flow	8.80M	6.03M	-13.45M	38.32M	25.68M	278.94M
Investing Cash Flow	5.83M	1.03M	-43.05M	10.88M	18.47M	-119.01M
Financing Cash Flow	-11.87M	-5.35M	-32.14M	-13.37M	-27.41M	-73.82M

Pharma Mar SA Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 86.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:PHM, the sentiment is Neutral. The current price of 86.8 is below the 20-day moving average (MA) of 87.28, above the 50-day MA of 83.31, and above the 200-day MA of 82.91, indicating a neutral trend. The MACD of 1.43 indicates Positive momentum. The RSI at 51.41 is Neutral, neither overbought nor oversold. The STOCH value of 29.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ES:PHM.

Pharma Mar SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FAE	73 Outperform	1.32B	12.47	15.34%	4.24%	11.04%	8.29%
ROVI	71 Outperform	2.94B	22.57	23.47%	1.61%	-3.73%	-7.56%
PHM	64 Neutral	$1.58B	37.06	21.61%	0.92%	19.18%	―
RJF	60 Neutral	230.31M	34.24	4.85%	1.74%	0.58%	-30.60%
ALM	53 Neutral	2.46B	113.80	1.46%	1.37%	13.32%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Pharma Mar SA Corporate Events

Pharma Mar Concludes Share Buy-back Program Early

Pharma Mar SA has completed its share buy-back program ahead of schedule, acquiring a total of 91,111 shares, which represents 0.5% of its share capital, for over 7.5 million euros. The completion of this program will lead to the amortization of these shares through a share capital reduction, and the resumption of operations under a liquidity contract with JB Capital Markets from June 23, 2025.

The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.

Pharma Mar SA Announces Dividend Payment for 2025

Pharma Mar SA announced the payment of a dividend from its share premium reserve, set to be distributed on June 27, 2025, at a net amount of 0.80 euros per share. This move reflects the company’s commitment to providing value to its shareholders and could enhance its market position by demonstrating financial stability and shareholder-friendly policies.

The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.

Pharma Mar S.A. Shareholders Approve Board Proposals

Pharma Mar S.A. held its Ordinary General Meeting of shareholders, where all proposals from the Board of Directors were approved by a sufficient majority. The outcomes of the meeting will be published on the company’s website within five days, reflecting the company’s commitment to transparency and shareholder engagement.

The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.

Pharma Mar’s Strategic Shareholder Meeting

Pharma Mar SA announced that its Chairman and Chief Financial Officer will present to shareholders at the Ordinary General Meeting in Colmenar Viejo, Madrid. This meeting is significant for stakeholders as it provides insights into the company’s current operations and future strategies.

The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.

Pharma Mar’s Zepzelca® Shows Promising Results in Lung Cancer Treatment

Pharma Mar SA announced positive results from the phase 3 IMforte study, showcasing the effectiveness of Zepzelca® (lurbinectedin) combined with atezolizumab as a first-line maintenance treatment for advanced-stage small cell lung cancer (SCLC). The study demonstrated significant improvements in progression-free and overall survival, marking a potential new standard in SCLC treatment. The results were presented at the ASCO meeting and published in The Lancet, with a marketing authorization application submitted to the European Medicines Agency.

The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.

Pharma Mar SA Reports on Recent Share Buy-Back Activities

Pharma Mar SA has reported on its share buy-back program activities conducted between May 19 and May 23, 2025. During this period, the company purchased a total of 6,500 shares at varying prices on the BME trading center. This buy-back initiative is part of the company’s strategy to stabilize its stock and potentially enhance shareholder value.

The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.

PharmaMar Seeks EMA Approval for New Lung Cancer Treatment

PharmaMar has submitted a marketing authorization application to the European Medicines Agency for Zepzelca® in combination with atezolizumab for first-line maintenance treatment in adult patients with advanced-stage small cell lung cancer. This application is based on significant results from the Phase 3 IMforte trial, highlighting the potential impact on PharmaMar’s operations and its positioning in the oncology market.

The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.

Pharma Mar SA Updates on Share Buy-Back Program

Pharma Mar SA has reported on its recent share buy-back program activities conducted between May 12 and May 16, 2025. This initiative is part of the company’s strategy to stabilize its stock and potentially enhance shareholder value, reflecting a proactive approach to managing its market presence.

The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.

Pharma Mar Gains Approval for Cancer Drug in Argentina

Pharma Mar S.A., along with its partner Adium Pharma S.A., has received conditional marketing approval in Argentina for Zepzelca® (lurbinectedin) for the treatment of metastatic small cell lung cancer (SCLC). This approval, based on clinical trial data, expands the availability of lurbinectedin to 18 territories globally, reinforcing Pharma Mar’s position in the oncology market and providing a new treatment option for a particularly aggressive form of lung cancer.

The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.

Pharma Mar’s Zepzelca® Gains Approval in Argentina for SCLC Treatment

Pharma Mar SA, in partnership with Adium Pharma SA, has received conditional marketing approval in Argentina for Zepzelca® (lurbinectedin) to treat metastatic small cell lung cancer (SCLC) in adults. This approval, based on clinical trial data, expands the availability of lurbinectedin to 18 territories globally, highlighting its growing impact in cancer treatment markets, particularly in Latin America.

The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.